66380 Federal Register / Vol. 75, No. 208 / Thursday, October 28, 2010 / Notices 

E-mail comments to 

paperwork@hrsa.gov or mail the HRSA 

Reports Clearance Officer, Room 10–33, 

Parklawn Building, 5600 Fishers Lane, 

Rockville, Maryland 20857. Written 

comments should be received within 60 

days of this Notice. 

Dated: October 21, 2010. 

Robert Hendricks, 

Director, Division of Policy and Information 

Coordination. 

[FR Doc. 2010–27286 Filed 10–27–10; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Health Resources and Services 

Administration 

Agency Information Collection 

Activities: Submission for OMB 

Review; Comment Request 

Periodically, the Health Resources 

and Services Administration (HRSA) 

publishes abstracts of information 

collection requests under review by the 

Office of Management and Budget 

(OMB), in compliance with the 

Paperwork Reduction Act of 1995 (44 

U.S.C. Chapter 35). To request a copy of 

the clearance requests submitted to 

OMB for review, e-mail 

paperwork@hrsa.gov or call the HRSA 

Reports Clearance Office on (301) 443– 

1129. 

The following request has been 

submitted to the Office of Management 

and Budget for review under the 

Paperwork Reduction Act of 1995. 

Proposed Project: National Health 

Service Corps Information Follow-up 

Form—New 

The National Health Service Corps 

(NHSC) of the Bureau of Clinician 

Recruitment and Service, HRSA, is 

committed to improving the health of 

the Nation’s underserved by uniting 

communities in need with caring health 

professionals and by supporting 

communities’ efforts to build better 

systems of care. 

The NHSC Information Follow-up 

Form, which NHSC will use when 

exhibiting at national and regional 

conferences as well as when presenting 

on campuses to health profession 

students, is an optional form that a 

health profession student, licensed 

clinician, faculty member, or clinical 

site administrator can fill out. 

Individuals who submit the form to 

NHSC, may ask questions and/or sign 

up to receive periodic program updates 

and other general information regarding 

opportunities with the NHSC via e-mail. 

An individual is free to discontinue 

receiving communication from NHSC at 

anytime by e-mailing 

NHSCupdate@hrsa.gov. Completed 

forms will contain information such as, 

the names of the individuals, their email 

address(es), their city and state, their 

phone number, the organization where 

they are employed (or the school which 

they attend), the year they intend to 

graduate (if applicable), how they heard 

about NHSC, which NHSC programs 

they are interested in, etc. Assistance in 

completing the form will be given by the 

BCRS staff person (or BCRS 

representative) who is present at the 

event. Based on the FY10 exhibit and 

presentation schedule, NHSC could 

have gathered information from 2,400 

individuals. Using this as a guide for 

future years, the estimated annual 

burden is as follows: 

Form Number of 

respondents 

Responses 

per 

respondent 

Total 

responses 

Hours per 

response 

Total 

burden 

hours 

Information Follow-up Form .............................................. 2400 1 2400 .025 (90 seconds).60 

Total ........................................................................... 2400 1 2400 .025 (90 seconds).60 

Written comments and 

recommendations concerning the 

proposed information collection should 

be sent within 30 days of this notice to 

the desk officer for HRSA, either by email to OIRA_submission@omb.eop.gov 

or by fax to 202–395–6974. Please direct 

all correspondence to the ‘‘attention of 

the desk officer for HRSA.’’ 

Dated: October 20, 2010. 

Robert Hendricks, 

Director, Division of Policy and Information 

Coordination. 

[FR Doc. 2010–27284 Filed 10–27–10; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Administration for Children and 

Families 

Award of a Single-Source Grant to the 

Commonwealth Election Commission 

of Saipan, Commonwealth of the 

Northern Mariana Islands (CNMI) 

AGENCY: Administration on 

Developmental Disabilities, ACF, HHS. 

ACTION: Notice. 

CFDA Number: 93.631. 

Statutory Authority: This award will 

be made pursuant to Section 161 of the 

Developmental Disabilities Assistance 

and Bill of Rights Act of 2000 (42 U.S.C. 

15081–15083). 

Amount of Award: $100,000. 

Project Period: 9/30/2010–9/29/2011. 

SUMMARY: This notice announces that 

the Administration for Children and 

Families (ACF), Administration on 

Developmental Disabilities (ADD) has 

awarded a single-source grant to the 

Commonwealth Election Commission of 

Saipan, Commonwealth of the Northern 

Mariana Islands (CNMI). 

In 2002, Congress enacted the Help 

America Vote Act (HAVA) [(Pub. L. 

107–252] as a means of improving the 

administration of elections for Federal 

office. CNMI did not participate in 

Federal elections prior to the enactment 

of the Consolidated Natural Resources 

Act of 2008 (Pub. L. 110–229). CNMI 

has now elected a non-voting Delegate 

to the U.S. House of Representatives. 

With its participation in Federal 

elections, CNMI’s eligibility for funding 

under HAVA is now established and, to 

that end, ADD is funding this award for 

a project designed to (1) Explore 

accessibility of polling places; (2) 

provide training and technical 

assistance to election officials, poll 

workers, and election volunteers on the 

best methods to promote the access and 

participation of individuals with 

developmental disabilities in elections 

for Federal office; and (3) train voters on 

how to use voting equipment to include 


emcdonald on DSK2BSOYB1PROD with NOTICES
Federal Register / Vol. 75, No. 208 / Thursday, October 28, 2010 / Notices 66381 

various voting machines to allow for 

equal opportunity for access and 

participation in the voting process. 

FOR FURTHER INFORMATION CONTACT: 

Ophelia McLain, Supervisory Program 

Specialist, Administration on 

Developmental Disabilities, 370 

L’Enfant Promenade, SW., Mail Stop: 

HHH–405D, Washington, DC 20447. 

Telephone: 202–690–7025. E-mail: 

ophelia.mclain@acf.hhs.gov. 

Dated: October 21, 2010. 

Sharon Lewis, 

Commissioner, Administration on 

Developmental Disabilities. 

[FR Doc. 2010–27234 Filed 10–27–10; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2010–N–0001] 

Cellular, Tissue and Gene Therapies 

Advisory Committee; Notice of Meeting 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

This notice announces a forthcoming 

meeting of a public advisory committee 

of the Food and Drug Administration 

(FDA). The meeting will be open to the 

public. 

Name of Committee: Cellular, Tissue 

and Gene Therapies Advisory 

Committee. 

General Function of the Committee: 

To provide advice and 

recommendations to the agency on 

FDA’s regulatory issues. 

Date and Time: The meeting will be 

held on November 19, 2010, from 8:30 

a.m. to 5 p.m. 

Location: Hilton Washington DC 

North/Gaithersburg 620 Perry Pkwy., 

Gaithersburg, MD 20877. 

Contact Person: Gail Dapolito or 

Sheryl Clark, Center for Biologics 

Evaluation and Research (HFM–71), 

Food and Drug Administration, 1401 

Rockville Pike, Rockville, MD 20852, 

301–827–0314, or FDA Advisory 

Committee Information Line, 1–800– 

741–8138 (301–443–0572 in the 

Washington, DC area), code 

3014512389. Please call the Information 

Line for up-to-date information on this 

meeting. A notice in the Federal 

Register about last minute modifications 

that impact a previously announced 

advisory committee meeting cannot 

always be published quickly enough to 

provide timely notice. Therefore, you 

should always check the agency’s Web 

site and call the appropriate advisory 

committee hot line/phone line to learn 

about possible modifications before 

coming to the meeting. 

Agenda: On November 19, 2010, the 

Committee will discuss current FDA 

recommendations for Testing of 

Replication Competent Retrovirus 

(RCR)/Lentivirus (RCL) in Retroviral 

and Lentiviral Vector Based Gene 

Therapy Products. 

FDA intends to make background 

material available to the public no later 

than 2 business days before the meeting. 

If FDA is unable to post the background 

material on its Web site prior to the 

meeting, the background material will 

be made publicly available at the 

location of the advisory committee 

meeting, and the background material 

will be posted on FDA’s Web site after 

the meeting. Background material is 

available at http://www.fda.gov/ 

AdvisoryCommittees/Calendar/ 

default.htm. Scroll down to the 

appropriate advisory committee link. 

Procedure: Interested persons may 

present data, information, or views, 

orally or in writing, on issues pending 

before the committee. Written 

submissions may be made to the contact 

person on or before November 12, 2010. 

Oral presentations from the public will 

be scheduled between approximately 2 

p.m. to 3 p.m. Those desiring to make 

formal oral presentations should notify 

the contact person and submit a brief 

statement of the general nature of the 

evidence or arguments they wish to 

present, the names and addresses of 

proposed participants, and an 

indication of the approximate time 

requested to make their presentation on 

or before November 4, 2010. Time 

allotted for each presentation may be 

limited. If the number of registrants 

requesting to speak is greater than can 

be reasonably accommodated during the 

scheduled open public hearing session, 

FDA may conduct a lottery to determine 

the speakers for the scheduled open 

public hearing session. The contact 

person will notify interested persons 

regarding their request to speak by 

November 5, 2010. 

Persons attending FDA’s advisory 

committee meetings are advised that the 

agency is not responsible for providing 

access to electrical outlets. 

FDA welcomes the attendance of the 

public at its advisory committee 

meetings and will make every effort to 

accommodate persons with physical 

disabilities or special needs. If you 

require special accommodations due to 

a disability, please contact Gail Dapolito 

at least 7 days in advance of the 

meeting. 

FDA is committed to the orderly 

conduct of its advisory committee 

meetings. Please visit our Web site at 

http://www.fda.gov/ 

AdvisoryCommittees/ 

AboutAdvisoryCommittees/ 

ucm111462.htm for procedures on 

public conduct during advisory 

committee meetings. 

Notice of this meeting is given under 

the Federal Advisory Committee Act (5 

U.S.C. app. 2). 

Dated: October 22, 2010. 

Jill Hartzler Warner, 

Acting Associate Commissioner for Special 

Medical Programs. 

[FR Doc. 2010–27229 Filed 10–27–10; 8:45 am] 

BILLING CODE 4160–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2010–N–0553] 

Pediatric Advisory Committee; Notice 

of Meeting 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

This notice announces a forthcoming 

meeting of a public advisory committee 

of the Food and Drug Administration 

(FDA). The meeting will be open to the 

public. 

Name of Committee: Pediatric 

Advisory Committee. 

General Function of the Committee: 

To provide advice and 

recommendations to the Agency on 

FDA’s regulatory issues. 

DATES: The meeting will be held on 

December 6, 2010, from 8 a.m. to 6 p.m. 

FDA is opening a docket to allow for 

additional public comments to be 

submitted to the Agency on the issues 

before the Pediatric Advisory 

Committee. Submit either electronic or 

written comments by January 6, 2011. 

ADDRESSES: The meeting will be held at 

the Bethesda Marriott, 5151 Pooks Hill 

Rd., Bethesda, MD 20814. 

Submit electronic comments to http://

www.regulations.gov. Submit written 

comments to the Division of Dockets 

Management (HFA–305), Food and Drug 

Administration, 5630 Fishers Lane, rm. 

1061, Rockville, MD 20852. 

Contact Person: Walter Ellenberg, 

Office of Pediatric Therapeutics, Office 

of Special Medical Programs, Office of 

the Commissioner, Food and Drug 

Administration, 10903 New Hampshire 

Ave., Bldg. 32, rm. 5154, Silver Spring, 

MD 20993, 301–796–0885, or FDA 


emcdonald on DSK2BSOYB1PROD with NOTICES